Clinician Article

Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials.

  • Palmerini T
  • Benedetto U
  • Bacchi-Reggiani L
  • Della Riva D
  • Biondi-Zoccai G
  • Feres F, et al.
Lancet. 2015 Jun 13;385(9985):2371-82. doi: 10.1016/S0140-6736(15)60263-X. Epub 2015 Mar 14. (Review)
PMID: 25777667
Read abstract Read evidence summary
  • Internal Medicine
    Relevance - 7/7
    Newsworthiness - 6/7
  • Cardiology
    Relevance - 6/7
    Newsworthiness - 6/7
  • Hematology
    Relevance - 5/7
    Newsworthiness - 7/7
  • Hemostasis and Thrombosis
    Relevance - 5/7
    Newsworthiness - 7/7


BACKGROUND: Despite recent studies, the optimum duration of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent placement remains uncertain. We performed a meta-analysis with several analytical approaches to investigate mortality and other clinical outcomes with different DAPT strategies.

METHODS: We searched Medline, Embase, Cochrane databases, and proceedings of international meetings on Nov 20, 2014, for randomised controlled trials comparing different DAPT durations after drug-eluting stent implantation. We extracted study design, inclusion and exclusion criteria, sample characteristics, and clinical outcomes. DAPT duration was categorised in each study as shorter versus longer, and as 6 months or shorter versus 1 year versus longer than 1 year. Analyses were done by both frequentist and Bayesian approaches.

FINDINGS: We identified ten trials published between Dec 16, 2011, and Nov 16, 2014, including 31,666 randomly assigned patients. By frequentist pairwise meta-analysis, shorter DAPT was associated with significantly lower all-cause mortality compared with longer DAPT (HR 0·82, 95% CI 0·69-0·98; p=0·02; number needed to treat [NNT]=325), with no significant heterogeneity apparent across trials. The reduced mortality with shorter compared with longer DAPT was attributable to lower non-cardiac mortality (0·67, 0·51-0·89; p=0·006; NNT=347), with similar cardiac mortality (0·93, 0·73-1·17; p=0.52). Shorter DAPT was also associated with a lower risk of major bleeding, but a higher risk of myocardial infarction and stent thrombosis. We noted similar results in a Bayesian framework with non-informative priors. By network meta-analysis, patients treated with 6-month or shorter DAPT and 1-year DAPT had higher risk of myocardial infarction and stent thrombosis but lower risk of mortality compared with patients treated with DAPT for longer than 1 year. Patients treated with DAPT for 6 months or shorter had similar rates of mortality, myocardial infarction, and stent thrombosis, but lower rates of major bleeding than did patients treated with 1-year DAPT.

INTERPRETATION: Although treatment with DAPT beyond 1 year after drug-eluting stent implantation reduces myocardial infarction and stent thrombosis, it is associated with increased mortality because of an increased risk of non-cardiovascular mortality not offset by a reduction in cardiac mortality.


Clinical Comments


As a practicing cardiologist, I find this information very thought-provoking. Many post-PCI patients are kept on Plavix for much too long.


At my institution (and many others with which I am familiar), interventional cardiologists make decisions in this area -- hematologists get involved only in a minority of unusual cases. I found this report very interesting, but our cardiologists are the ones who have the expertise to fully interpret the findings.

Internal Medicine

The long-term follow-up of dual antiplatelets often falls to non-cardiologists as comorbidities, events, and other medications require oversight. The optimal duration of DAPT for drug-eluting and bare-metal stents is a constant source of frustration due to lack of well validated clinical prediction rules of benefit vs harm.

Internal Medicine

Good meta-analysis of long-term dual antiplatelet therapy, even though it is now recommended for only 1 year. It is good to know that all-cause mortality is higher with longer therapy.

Internal Medicine

This is an important issue. What I don't know is whether this analysis supports their conclusion. This needs to be carefully looked at by an experienced methodologist to make sure the data support the conclusion.

Register for free access to all Professional content

Want the latest in aging research? Sign up for our email alerts.

Support for the Portal is largely provided by the Labarge Optimal Aging Initiative. AGE-WELL is a contributing partner. Help us to continue to provide direct and easy access to evidence-based information on health and social conditions to help you stay healthy, active and engaged as you grow older. Donate Today.

© 2012 - 2020 McMaster University | 1280 Main Street West | Hamilton, Ontario L8S4L8 | +1 905-525-9140 | Terms Of Use